Abstract IA27: Context-dependent role of KRAS in GI malignancies

作者
Wenting Liao,Michael James Overman,Adam T. Boutin,Prasenjit Dey,Di Zhao,Guocan Wang,Jiexi Li,Zhengdao Lan,Jun Li,Xiaoying Shang,Ming‐Jer Tang,Shan Jiang,Xingdi Ma,Peiwen Chen,Riham Katkhuda,Krittiya Korphaisarn,Deepavali Chakravarti,Qing Chang,Jianhua Zhang,Dipen Maheshbhai Maru
出处
期刊:Molecular Cancer Research [American Association for Cancer Research]
卷期号:18 (5_Supplement): IA27-IA27
标识
DOI:10.1158/1557-3125.ras18-ia27
摘要

Abstract Oncogenic Kras (Kras*) plays a key role in tumor maintenance and therapeutic resistance in several cancer types, although the precise biologic functions and mechanisms are not completely understood. We had previously shown in pancreatic ductal adenocarcinoma that some tumors underwent spontaneous relapse and were devoid of Kras* expression and downstream canonical MAPK signaling, instead acquiring amplification and overexpression of the transcriptional coactivator Yap1. Functional studies established the role of Yap1 and the transcriptional factor Tead2 in driving Kras*-independent tumor maintenance. In a second previous study, we developed a faithful colorectal cancer (CRC) mouse model and showed that Kras* drove invasion and maintenance in CRC. Here, utilizing this CRC mouse model, we demonstrate that KRAS* promotes a pronounced immune-suppressive profile distinguished by a predominance of myeloid-derived suppressor cells (MDSCs). We performed integrated transcriptomic and genomic analyses that identified IRF2 (Interferon Regulatory Factor 2) as a key KRAS* effector mediating immune suppression. IRF2 suppresses MDSC migration and infiltration in KRAS*-expressing CRC tumors by targeting the CXCL3/CXCR2 axis. We also observed that de novo resistance of KRAS*-expressing tumors to anti-PD1 therapy could be overcome by enforced IRF2 expression or by treatment with SX-682, a small-molecule CXCR2 antagonist. In addition, CRC patient tumors with higher IRF2 expression showed increased response to anti-PD1 therapy. This KRAS*-mediated immune-suppressive mechanism provides a framework for CRC patient selection and combination therapies to enhance the effectiveness of immune checkpoint blockade therapy in advanced disease. Citation Format: Wen-Ting Liao, Michael J. Overman, Adam Boutin, Prasenjit Dey, Di Zhao, Guocan Wang, Jiexi Li, Zhengdao Lan, Jun Li, Xiaoying Shang, Ming Tang, Shan Jiang, Xingdi Ma, Peiwen Chen, Riham Katkhuda, Krittiya Korphaisarn, Deepavali Chakravarti, Qing Chang, Jianhua Zhang, Dipen M. Maru, Dean Y. Maeda, John A. Zebala, Scott Kopetz, Y. Alan Wang, Ronald A. DePinho. Context-dependent role of KRAS in GI malignancies [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr IA27.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Jasper的应助被jhcdgszjdcb采纳,获得10
刚刚
勤奋乌龟发布了新的文献求助10
1秒前
1秒前
1秒前
蓝懒懒完成签到 ,获得积分10
2秒前
隐形曼青的应助被jdw采纳,获得20
2秒前
2秒前
羊的糕发布了新的文献求助10
2秒前
能干觅珍发布了新的文献求助20
2秒前
jie发布了新的文献求助10
2秒前
小二郎的应助被西瓜皮采纳,获得10
2秒前
彩色的朋发布了新的文献求助10
3秒前
3秒前
传奇3的应助被pp009900采纳,获得10
3秒前
3秒前
大胆绿柳发布了新的文献求助10
3秒前
hanli发布了新的文献求助10
4秒前
4秒前
大雪纷飞发布了新的文献求助10
4秒前
4秒前
hahaha发布了新的文献求助30
4秒前
yoshi发布了新的文献求助10
5秒前
领导范儿的应助被酷酷柚子采纳,获得10
5秒前
5秒前
深情安青的应助被五五Rcwt采纳,获得10
5秒前
东方欲晓发布了新的文献求助30
5秒前
5秒前
6秒前
共享精神的应助被顺利汉堡采纳,获得30
6秒前
7秒前
8秒前
Hello的应助被Ceylon采纳,获得10
8秒前
变形金刚发布了新的文献求助10
8秒前
9秒前
msk发布了新的文献求助10
9秒前
细腻的渊思完成签到 ,获得积分20
9秒前
9秒前
高高冷风发布了新的文献求助10
9秒前
科研通AI6.3的应助被dzx采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178341
求助须知:如何正确求助?哪些是违规求助? 9569073
关于积分的说明 21802629
捐赠科研通 7773188
什么是DOI,文献DOI怎么找? 3432780
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478298